Bertram Glaß

Plerixafor in poor mobilizers with non-Hodgkin’s lymphoma: a multi-center time-motion analysis

Mohamad Mohty, Nabih Azar, Christian Chabannon et al. · Bone Marrow Transplantation · 2017 · 38 citations · Full text

Medicine, Hematology, Oncology +17

Allogeneic or autologous transplantation as first-line therapy for younger patients with peripheral T-cell lymphoma: Results of the interim analysis of the AATT trial.

Norbert Schmitz, Maike Nickelsen, Bettina Altmann et al. · Journal of Clinical Oncology · 2015 · 32 citations

Medicine, Oncology, Cell Therapy +11

ZUMA-23: A global, phase 3, randomized controlled study of axicabtagene ciloleucel versus standard of care as first-line therapy in patients with high-risk large B-cell lymphoma.

Jason R. Westin, Caron A. Jacobson, Julio C. Chávez et al. · Journal of Clinical Oncology · 2023 · 19 citations

Medicine, Hematology, Oncology +15

Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with 131I-anti-CD20 antibody and stem cell rescue

Karin Hohloch, Carsten Oliver Sahlmann, Vijai J. Lakhani et al. · Annals of Hematology · 2011 · 16 citations · Full text

Medicine, Hematology, Oncology +17

Lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (pt) with R/R large B-cell lymphoma (LBCL): 3-year follow-up (FU) from the randomized, phase 3 TRANSFORM study.

Manali Kamdar, Scott R. Solomon, Jon Arnason et al. · Journal of Clinical Oncology · 2024 · 16 citations

Medicine, Oncology, Chemotherapy +14